Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03215030 · OUTCOME

Part 3: Percentage of Participants With Clinically Significant Laboratory Values

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma · Source last updated 2026-01-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 20.5 months in Part 3

What was measured

Laboratory values included hematology, chemistry, and urinalysis as interpreted by the investigator.

Analysis population: FAS:all participants who took ≥1 dose,even if incomplete,of TAK-573 in Part 3 extension cohorts.However,clinically significant laboratory values data were not collected\&will never be available to present due to issue with report form used for data collection(identified after trial completion).Assessments of clinical significance were not included in report form,making data collection impossible.This issue did not impact participant safety/reliability of study data,particularly primary endpoint.

Groups in this outcome

Part 3 (Dose Extension): Modakafusp Alfa 120 mg

Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Part 3 (Dose Extension): Modakafusp Alfa 240 mg

Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 3 (Dose Extension): Modakafusp Alfa 120 mg0
Part 3 (Dose Extension): Modakafusp Alfa 240 mg0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Laboratory values included hematology, chemistry, and urinalysis as interpreted by the investigator.
groups
  1. description
    Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
    id
    OG000
    title
    Part 3 (Dose Extension): Modakafusp Alfa 120 mg
  2. description
    Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
    id
    OG001
    title
    Part 3 (Dose Extension): Modakafusp Alfa 240 mg
population Description
FAS:all participants who took ≥1 dose,even if incomplete,of TAK-573 in Part 3 extension cohorts.However,clinically significant laboratory values data were not collected\&will never be available to present due to issue with report form used for data collection(identified after trial completion).Assessments of clinical significance were not included in report form,making data collection impossible.This issue did not impact participant safety/reliability of study data,particularly primary endpoint.
reporting Status
POSTED
time Frame
Up to 20.5 months in Part 3
title
Part 3: Percentage of Participants With Clinically Significant Laboratory Values
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice